Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib mesylate in recurrent or metastatic head and neck squamous cell carcinoma after chemotherapy failure
ChiCTR1800015278Phase 2Recruiting
- Sponsor
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Start
- Jul 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Primary endpoints: progression-free survival and safety. Started Jul 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR1800015278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015278.